mTOR inhibitors a potential predisposing factor for chronic hepatitis E: Results from the prospective collaborative CHES study (Chronic Hepatitis EScreening in patients with immune impairment and increased transaminases levels)

Gastroenterol Hepatol. 2023 Dec;46(10):764-773. doi: 10.1016/j.gastrohep.2023.01.010. Epub 2023 Jan 31.
[Article in English, Spanish]

Abstract

Background: Chronic hepatitis E virus (HEV) in persons with immune impairment has a progressive course leading to a rapid progression to liver cirrhosis. However, prospective data on chronic HEV is scarce. The aim of this study was to determine the prevalence and risk factors for chronic HEV infection in subjects with immune dysfunction and elevated liver enzymes.

Patients and methods: CHES is a multicenter prospective study that included adults with elevated transaminases values for at least 6 months and any of these conditions: transplant recipients, HIV infection, haemodialysis, liver cirrhosis, and immunosuppressant therapy. Anti-HEV IgG/IgM (Wantai ELISA) and HEV-RNA by an automated highly sensitive assay (Roche diagnostics) were performed in all subjects. In addition, all participants answered an epidemiological survey.

Results: Three hundred and eighty-one patients were included: 131 transplant recipients, 115 cirrhosis, 51 HIV-infected subjects, 87 on immunosuppressants, 4 hemodialysis. Overall, 210 subjects were on immunosuppressants. Anti-HEV IgG was found in 94 (25.6%) subjects with similar rates regardless of the cause for immune impairment. HEV-RNA was positive in 6 (1.6%), all of them transplant recipients, yielding a rate of chronic HEV of 5.8% among solid-organ recipients. In the transplant population, only therapy with mTOR inhibitors was independently associated with risk of chronic HEV, whereas also ALT values impacted in the general model.

Conclusions: Despite previous abnormal transaminases values, chronic HEV was only observed among solid-organ recipients. In this population, the rate of chronic HEV was 5.8% and only therapy with mTOR inhibitors was independently associated with chronic hepatitis E.

Keywords: Chronic hepatitis E; Cirrosis hepática; HIV infection; Hepatitis E virus; Hepatitis crónica E; Immunosuppression; Infección por VIH; Inhibidores de mTOR; Inmunosupresión; Liver cirrhosis; Solid-organ transplant; Trasplante de órgano sólido; Virus de la hepatitis E; mTOR inhibitors.

Publication types

  • Multicenter Study

MeSH terms

  • Adult
  • HIV Infections
  • Hepatitis Antibodies / therapeutic use
  • Hepatitis E* / epidemiology
  • Hepatitis, Chronic / epidemiology
  • Humans
  • Immunoglobulin G
  • Immunosuppressive Agents* / adverse effects
  • Liver Cirrhosis / complications
  • MTOR Inhibitors* / adverse effects
  • MTOR Inhibitors* / therapeutic use
  • Prospective Studies
  • RNA, Viral / analysis
  • Risk Factors
  • Transaminases

Substances

  • 2-(N-cyclohexylamino)ethanesulfonic acid
  • Hepatitis Antibodies
  • Immunoglobulin G
  • Immunosuppressive Agents
  • MTOR Inhibitors
  • RNA, Viral
  • Transaminases